natgillin/translations-raw huggingface dataset:
and R2 are the same or different, and represent hydrogen or alkyl groups, 
- R1 iR> su jednaki ili različiti, 1 predstavljaju vodik ili alkilne skupine,
W is a group of formula (Wb); wherein 
W je skupina formule (W,) definirana kao u zahtjevu 2;
The cuboidal housing according to claim 2, wherein the borders of the outer wall (6) or of the inner wall (5) is angled in the direction of the corresponding insulating means (7). 
Kućište (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time, što je vanjska stijenka (6) i/ili unutarnja stijenka (5) je/jesu nagnuti na rubnoj strani u smjeru odgovarajućeg izolacijskog komada (7).
“Halogen” or “halo” may be fluorine, chlorine, bromine or iodine; preferably it is bromine or chlorine or fluorine. 
"Halogen" ili "halo" može biti fluor, klor, brom ili jod; to je ponajprije brom ili klor ili fluor.
PCR primer identified by any of the sequences selected from the group consisting of SEQ ID NO: 2-3, SEQ ID NO: 5-6, SEQ ID NO: 8-9 and SEQ ID NO: 11-12. 
par nukleinskokiselinskih početnica koje mogu specifično amplificirati najmanje jedan 16S rDNA slijed kojeg se bira iz spiska kojeg čine SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 i SEQ ID NO:10; i
wherein, when the one available intra prediction mode is a DC mode, the two additional intra prediction modes include a planar mode and the vertical mode, and 
Metoda prema zahtjevu 1, naznačena time da je dostupni unutarokovirni načina predviđanja DC način, dva dodatna unutarokovirna načina predviđanja uključuje planarni 1 vertikalni način.
These include less efficient use of oxygen for ATP production, activation of mitochondrial fatty acid oxidation and possibly, promotion of cell necrosis. 
Ovo obuhvaća manje učinkovitu uporabu kisika za ATP proizvodnju, aktiviranje oksidacije mitohondrialnih masnih kiselina i moguće, promociju nekroze stanice.
wherein: R is selected from the group consisting of hydrogen; C1-8 alkyl; C3-6cycloalkyl; (C3-6)cycloalkyl(C1-3)alkyl; phenyl(C1-3)alkyl; and phenyl(C1-3)alkyl substituted with 1-3 members of the group consisting of C1-8 alkyl, trifluoromethyl, nitro, dialkylamino and cyano; 
R je odabran iz skupine koja se sastoji od vodika; Ci.g alkila; Ca4 cikloalkila; (Cz.g)cikloalkil(C; 3) alkila; feni(C.. z)alkila; i feniKC, s)alkila supstituiranog s 1-3 člana skupine koja se sastoji od C,.g alkila, trifluorometila, nitro, dialkilamino i cijano;
The compound of any one of claims 1 to 5, wherein A is a ring selected from the group consisting of phenyl, pyridine, pyrimidine, pyridazine, pyrazine, triazine, pyrazole, imidazole, triazole, tetrazole, thiazole, isothiazole, oxazole and isoxazole, or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je A prsten kojeg se bira iz skupine koju čine fenil, piridin, pirimidin, piridazin, pirazin, triazin, pirazol, imidazol, triazol, tetrazol, tiazol, izotiazol, oksazol i izoksazol, ili njegova farmaceutski prihvatljiva sol.
Thus, in some embodiments, the methods comprise combining a compound of Formula I, a pharmaceutically acceptable salt thereof, or a mixture of any two or more thereof, with an ingredient selected from a hydrophilic solvent, a lipophilic solvent, an emulsifier, or a mixture of any two or more thereof to form a formulation. 
Formulacija, naznačena time, da sadrži spoj formule I, njegovu farmaceutski prihvatljivu sol, ili mješavinu od bilo koja dva ili više od istih; i sastojak odabran između hidrofilnog otapala, lipofilnog otapala, emulzifikatora, ili mješavine od bilo koja dva ili više od istih; pri čemu spoj formule I je:
The process of claim 1, wherein the curing step c) takes place in an oven with an inside temperature. The process of claim 12, wherein the temperature of step c) is the target inside temperature of the oven and wherein the curing step starts when the inside temperature of the oven reaches said temperature, and the curing step ends either when the heating is stopped or at least reduced and the inside temperature of the oven subsequently drops below said temperature by more than about 10° C. or below about 62° C., in a plateau-like temperature profile or when the inside temperature of the oven drops below said temperature in a parabolic or triangular temperature profile. 
Postupak prema bilo kojem zahtjevu od 1 do 11, naznačen time da se korak stvrdnjavanja c) odvija u peći s unutarnjom temperaturom, Postupak prema zahtjevu 12, naznačen time da je temperatura koraka c) ciljana unutarnja temperatura peći i gdje korak stvrdnjavanja počinje nakon što unutarnja temperatura peći dostigne navedenu temperaturu, i korak stvrdnjavanja završava ili kada se zaustavi zagrijavanje ili kada se barem reducira te unutarnja temperatura peći nakon toga pada ispod navedene temperature za više od oko 10?C ili ispod oko 62 *C, u temperaturnom profilu nalik platou ili kada unutarnja temperatura peći pada ispod navedene temperature u paraboličnom ili trokutastom temperaturnom profilu.
An antibody or FcRn-binding fragment thereof as defined in any one of claims 1 to 10 or a composition as defined in claim 16 or 17, for use in the treatment of CIDP, Para-proteinemic Polyneuropathy, Refractory Epilepsy, ITP/TTP, Hemolytic Anemia, Goodpasture's Syndrome, ABO mismatch, Lupus nephritis, Renal Vasculitis, Scleroderma, Fibrosing alveolitis, Dilated cardio-myopathy, Grave's Disease, Type 1 diabetes, Autoimmune diabetes, Pemphigus, ANCA vasculitis, Dermato-myositis, Sjogren's Disease and Rheumatoid Arthritis. 
Antitijelo ili njegov fragment koji se vezuje za FcRn kako je definirano u bilo kojem patentnom zahtjevu od 1 do 10 ili pripravak kako je definirano u patentnom zahtjevu 16 ili 17, za primjenu u liječenju kronične upalne demijelinacijske polineuropatije (CIDP), paraproteinemičke polineuropatije, refraktorne epilepsije, ITP/TTP-a, hemolitičke anemije, Goodpastureovog sindroma, nekompatibilnosti krvnih grupa ABO, lupusnog neffitisa, bubrežnog vaskulitisa, sklerodermije, fibroznog alveolitisa, dilatirane kardiomiopatije, Graveove bolesti, dijabetesa tipa 1, autoimunog dijabetesa, pemfigusa, ANCA-pozitivnog vaskulitisa, dermatomiozitisa, Sjorgenove bolesti i reumatoidnog artritisa.
According to a further aspect the present invention provides a noradrenaline injectable solution stable and substantially free of preservatives and/or anti-oxidizing agents, optionally containing an excipient, in which the concentration of noradrenaline is in the range of 0.04 to 0.2 mg/ml and pH is 3.2 to 3.6. 
Stabilna, injektabilna otopina noradrenalina s količinom konzervansa i/ili antioksidacijskih sredstava nižom od 0.005 težinskih %, pri čemu je otapalo otplinjena ili deaerirana voda, koncentracija noradrenalina je u opsegu od 0.04 do 0.2 mg/ml i pH je od 3.2 do 3.6 pomoću klorovodične kiseline.
It is supplied as a sterile, white-to-off-white lyophilized cake in single-use vials intended for intravenous (IV) administration. 
Isporučuje se kao sterilni bijeli do bjelkasti liofilizirani kolač u bočicama za jednokratnu uporabu namijenjen intravenoznom (IV) davanju.
Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinylpyrrolidone; fillers, for example, lactose, sugar, microcrystalline cellulose, maize-starch, calcium phosphate or sorbitol; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disintegrants, for example, potato starch or sodium starch glycollate, or wetting agents such as sodium lauryl sulphate. 
Tablete i kapsule za oralnu primjenu mogu sadržavati konvencionalni pomoćne tvari, poput veziva, primjerice sirupa, arapske gume, želatine, sorbitola, tragakanta, sluzi od škroba ili polivinilpirolidona; punila, primjerice laktoze, šećera, mikrokristalne celuloze, kukuruznog škroba, kalcijevog fosfata ili sorbitola; maziva, primjerice magnezijevog stearata, stearinske kiseline, talka, polietilen-glikola ili silicijevog dioksida; sredstava za raspadanje, primjerice krumpirovog škroba ili natrij-karboksimetilškroba; ili sredstava za vlaženje, poput natrijevog lauril-sulfata.
extracting Indigo Naturalis with ethanol at reflux between 2 and 8 hours, filtering the mixture at a temperature not less than 65°C to obtain a filtrate, concentrating the filtrate, to obtain a crude extract, said crude extract is optionally filtered (with addition of water) in order to remove completely the solvent and the last components still present in the solvent and dried, 
Postupak priprave rafiniranog ekstrakta iz prirodnog indiga, naznačen time što se sastoji u koracima: a) = ekstrahiranja prirodnog indiga etanolom na refluksu između 2 1 8 sati, b) filtriranja smjese na temperaturi od najmanje 65 "€ kako bi se dobilo filtrat, c) - koncentriranja filtrata kako bi se dobilo sirovi ekstrakt, gdje se navedeni sirovi ekstrakt može filtrirati (uz dodatak vode) kako bi se posve uklonilo otapalo i posljednje komponente koje su još prisutne u otapalu, te osušilo, d)
is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of hydrogen, halo, cyano, C1-4alkyl, C1-4alkyloxy, perfluoroC1-4alkyl, diC1-4alkylamino; thienyl; thienyl substituted with 1 or 2 substituents selected from the group consisting of halo and C1-4alkyl; C3-8cycloalkyl; or C5-7cycloalkenyl; 
je fenil; fenil supstituiran s 1, 2 ili 3 supstituenata pri čemu je svaki nezavisno odabran iz skupine koju čine vodik, halogen, cijano, C1-4alkil, C1-4alkiloksi, perfluoroC1-4alkil, diC1-4alkilamino; tienil; tienil supstituiran s 1 ili 2 supstituenta koji su odabrani iz skupine koju čine halogen i C1-4alkil; C3-8cikloalkil; ili C5-7cikloalkenil;
A glycosylated human Serum Amyloid P (SAP) polypeptide for use in inhibiting fibrocyte differentiation, wherein the SAP polypeptide comprises an N-linked oligosaccharide chain, and wherein at least one branch of the oligosaccharide chain terminates with a a2,3-linked sialic acid moiety. 
Glikozilirani humani serumski amiloidni P (SAP) polipeptid za upotrebu u inhibiranju diferencijacije monocita u fibrocite, naznačen time, da SAP polipeptid sadržava N-vezani oligosaharidni lanac i pri čemu barem jedna grana oligosaharidnog lanca završava s a2,3- vezanim ostatkom sijalične kiseline.
the pharmaceutically acceptable salts thereof, said process comprising the following steps: reacting a compound of formula (II) wherein X is defined as above and X' is selected from the group consisting of chlorine, bromine, iodine and a triflate group (CF3SO3) with a compound of formula (III) wherein R is defined as above to form a compound of formula (IV) 
X jest fluor, te predstavlja jedan ili više atoma halogena, naznačen time da rečeni postupak obuhvaća sljedeće korake: (1) reakcija spoja formule (II), X' DO X (ID u kojoj je X gore definiran, a X' je odabran iz sljedeće skupine: klor, brom, jod te triflatna skupina (CF3SO:), sa spojem formule (III)
The concentration of each of these two substances combined together was able to give the sub-maximal induction of production of IFN-Y on KG-1 cells. 
Koncentracija svake od dviju supstanci kombinirana skupa može dati sub-maksimalnu indukciju u proizvodnji INF-y na stanicama KG-1.
The fusion peptide according to claim 13, wherein the N-terminal His residue of GLP-1(GLP-1(7)) is chemically modified at its NH2 terminus and/or at its histidyl side chain, in particular by a hydrophobic moiety. 
Fuzijski peptid prema patentnom zahtjevu 14 ili 16, naznačen time da je N-terminalni His ostatak GLP-1 (GLP-1 (7)) kemijski modificiran na svojem NH, terminusu i/ili na svojem histidinskom bočnom lancu, posebice sa hidrofobnim dijelom.
reacting the compound of formula 4-ii with a compound of formula 4-iii: 
reakcijom spoja formule 4-iii: sa spojem formule 4-ii: pod pogodnim uvjetima cikloadicije.
While further cooling and stirring, the suspension is filled up with refrigerated propellant 227 to 1170 g and after mixing again filled in metal cans which are closed with metering valves releasing 50 ul of the suspension per actuation. 
Dok se dalje hladi i miješa, suspenzija se nadopuni ohlađenim propelantom 227 do 1170 g i nakon miješanja opet puni u metalne limenke koje su zatvorene mjernim ventilima koji otpuštaju 50 ul suspenzije po jednom aktiviranju.
The immunogenic composition for use according to claim 5 wherein said lipid A derivative is 3D-MPL. 
Imunogeni pripravak u skladu s patentnim zahtjevom 5, naznačen time što je navedeni derivat lipida A 3D-MPL.
It is known that the intestine is divided into two distinct portions: the proximal portion, called the “small intestine”, which is formed, in the craniocaudal direction, by the duodenum, the jejunum and the ileum, and the distal portion, called the “large intestine”, which is formed by the colon and the recto-anus (Faller A, Scevola G. Anatomia e Fisiologia del Corpo Umano (Anatomy and Physiology of the Human Body). 
Općenito gledano crijeva su podijeljena u dva određena dijela: proksimalni dio nazvan 1 "tanko crijevo" koji se gledano u smjeru glava-noge sastoji od dvanaesnika, jejunuma i ileuma, te u distalnog dijela nazvanog i "debelo crijevo" koji se sastoji od kolona i ravnog crijeva sa anusnim otvorom (Faller A, Scevola G. Anatomia e Fisiologia del Corpo Umano (Anatomy and Physiology of the Human Body).
is hydrogen, CH3 or CH2CH3, or R1 and the carbon to which it is bound form a C═CH2 group; 
je vodik, CH3, ili CH2CH3, ili R1 i ugljik na kojeg je vezan tvore skupinu C=CH2;
A method for the non-therapeutic, dermocosmetic treatment of skin, comprising the steps of: 
M» Postupak ne-terapeutskog, dermokozmetičkog tretmana kože, koji obuhvaća korake:
An embodiment of the instant invention provides a processes of culturing hemangioblasts that generate preparations of mesenchymal stromal cells, wherein said mesenchymal stromal cells retain a youthful phenotype. 
Postupak dobivanja mezenhimnih stromalnih stanica, naznačen time što se sastoji u uzgoju hemangioblasta u uvjetima u kojima se stanice diferenciraju u mezenhimne stromalne stanice.
In Figure 2, the stereochemistry of each isomer is defined using the "R and S" nomenclature developed by Cahn, Ingold and Prelog, see Advanced Organic Chemistry by Jerry March, 4th Edition, John Wiley & Sons, New York, 1992, pages 109-114 . 
Na Slici 2, stereokemija svakog izomera je određena uporabom "R i S" nomenklature zasnovane od Cahn, Ingold i Prelog, vidi Advanced Organic Chemistry od Jerry March, 4 Edition, John Wiley & Sons, New York, 1992, stranice 109-114.
Compounds of the formula 1 as claimed in claims 1 to 20 in which 
Spojevi formule I u skladu s patentnim zahtjevima 1 do 20, gdje
XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides, wherein XXX is complementary to X′X′X′, YYY is complementary to Y′Y′Y′, and ZZZ is complementary to Z′Z′Z′; and 
XXX, YYY, ZZZ, X'X'X', Y'Y'Y', i Z'Z'Z' svaki neovisno predstavljaju jedan motiv od tri identične modifikacije na tri uzastopna nukleotida; modifikacije na Nb se razlikuju od modifikacija na Y i modifikacije na Nb' se razlikuju od modifikacija na Y;
preventing formation or re-formation of tumors, and 
(v) spriječava formiranje i ponovno formiranje tumora, i
is 1-2C-alkoxy, or 1-2C-alkoxy predominantly or completely substituted by fluorine and is 1-2C-alkoxy, or 1-2C-alkoxy predominantly or completely substituted by fluorine, or and R2 together form a 1-2C-alkylenedioxy group, 
R1 je 1-2C-alkoksi, ili 1-2C-alkoksi pretežno ili potpuno supstituiran s fluorom i R2 je 1-2C-alkoksi ili 1-2C- alkoksi pretežno ili potpuno supstituiran s fluorom, ili R1 1 R2 zajedno tvore 1-2C-alkilendioksi-skupinu,
Example 4: Comparative studies of the stabilizer components 
Datum podnošenja europske prijave patenta:
The method of claim 17, wherein the recombinant nucleic acid coding for VKORC1 is stably expressed. 
Postupak prema zahtjevu 17, naznačen time, da se stabilno eksprimira rekombinantna nukleinska kiselina, koja kodira za VKORCI.
The method according to claim 6, wherein the crosslinked hyaluronic acid in said gel of hyaluronic acid is previously obtained from the crosslinking of a non-crosslinked hyaluronic acid with an effective amount of at least one crosslinking agent selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), 1,4-bis(2,3-epoxypropoxy)butane, 1,4-bisglycidyloxybutane, 1,2-bis(2,3-epoxypropoxy)ethylene, 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane, an endogenous polyamine, and a mixture thereof. 
Postupak prema patentnom zahtjevu 1, naznačen time što se umrežena hijaluronska kiselina iz koraka a) prethodno dobiva iz umrežavanja ne-umrežene hijaluronske kiseline s učinkovitom količinom najmanje jednog sredstva za umrežavanje koje se bira iz skupine koja sadrži 1,4-butandiol diglicidil eter.
S.D. A pharmaceutically acceptable composition of a parasiticidally effective, subtoxic amount of imidacloprid from 0.01 mg/kg body weight to 30 mg/kg body weight for use in a method to eliminate blood-sucking or consuming parasites on mammals, wherein imidacloprid is the only parasiticidal agent present in the pharmaceutical composition and wherein the parasites are ectoparasites and wherein the method comprises orally delivering said composition to said mammals. 
Farmaceutski prihvatljiv pripravak parazitocidno djelotvorne, subtoksične količine imidakloprida od 0,01 mg/kg tjelesne težine do 30 mg/kg tjelesne težine, namijenjen upotrebi u postupku uklanjanja parazita koji sišu ili konzumiraju krv na sisavcima, naznačen time što je imidakloprid jedini parazitocid prisutan u farmaceutskom pripravku, što su paraziti ektoparaziti, te što se postupak sastoji u oralnom unosu navedenog pripravka u navedene sisavce.
a second interface (84) with a second base body (1). 
- < drugi međusklop s drugim osnovnim tijelom (1).
A first therapeutic agent represented by the following structural formula: or a pharmaceutically acceptable salt thereof, for use in the treatment of Fabry disease, wherein said treatment comprises administrating an effective amount of the first therapeutic agent in combination with an effective amount of a second therapeutic agent that is effective for treating Fabry disease. 
Prvo terapijsko sredstvo predstavljeno sa slijedećom strukturnom formulom: O: ili njegova farmaceutski prihvatljiva sol, naznačeno time da je za upotrebu za liječenje Fabrijeve bolesti, pri čemu navedeno liječenje obuhvaća davanje učinkovite količine prvog terapijskog sredstva u kombinaciji s učinkovitom količinom drugog terapijskog sredstva koje je korisno za liječenje Fabrijeve bolesti.
The composition of claim 1, wherein the porogen hydrogel and/or the bulk hydrogel comprises a cross-linked alginate polymer comprising a divalent cation selected from the group consisting of Ca+2, Mg+2, and Ba+2. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što porogeni hidrogel i/ili volumni hidrogel sadrži umreženi alginatni polimer koji sadrži dvovalentni kation, kojeg se bira iz skupine koju čine Ca+2, Mg+2, te Ba+2.
primers comprising or consisting of the sequences of SEQ ID NOs. 
početnice sadržeći ili sastojeći se od sekvenci SEQ ID NOs.
the control program 18 then performs a reading of the code of the request (for example by means of the reading device 10) and cross-checks the validity of the request itself by asking an acknowledgment to the hospital data management system 17 through the communication module 19; 
A3) upravljački program tada obavlja čitanje koda zahtjeva (na primjer, pomoću uređaja za čitanje 10) i unakrsno ispituje vrijednost samog zahtijeva ispitivanjem potvrde sustava za upravljanje podacima 17 preko modula za komunikaciju 19;
A compound of any previous claim wherein the DP antagonist is: or a pharmaceutically acceptable salt or solvate thereof. 
[image] Spoj E nikotinske kiseline ili njene farmaceutski prihvatljive soli ili solvata i inhibitora HMG Co-A reduktaze.
mg of said oxycodone or pharmaceutically acceptable salt thereof, and at least 57% by weight of said high molecular weight polyethylene oxide; or 
mg ili 80 mg oksikodon hidroklorida; i pri čemu pripravak sadrži barem oko 60 % (težinski) polietilen oksida.
Use according to any one of the preceding claims wherein the compound is selected from a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a N -oxide form thereof. 
Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da je spoj odabran od [image] [image] njegova farmaceutski prihvatljiva kisela ili bazna adicijska sol, njegov stereokemijski izomerni oblik, njegov tautomerni oblik ili njegov oblik N-oksida.
A class of aptamers characterized by having high affinity for their corresponding target molecules and slow dissociation rates (t1/2) from a non-covalent complex of the aptamer and target is provided. With reference to FIG. 
Ne-kovalentni kompleks prema zahtjevu 6, naznačen time, da je brzina razdruživanja (ti/2) aptamera iz ciljane molekule, veća ili jednaka vremenu od 30 minuta.
a charge transporting material, which is a hole transporting material. An optoelectronic device according to any one of paragraphs 33, 34, and 41, wherein the porous layer of an n-type semiconductor comprises: an oxide of titanium, tin, zinc, niobium, tantalum, tungsten, indium, gallium, neodinium, palladium or cadmium. 
(c) materijal za prijenos naboja, koji je materijal za prijenos šupljina; po izboru, pri čemu porozni sloj poluvodiča n-tipa sadržava: oksid titana, kositra, cinka, niobija, tantala, volframa, indija, galija, neodiniuma, paladija ili kadmija, i poželjno sadržava TiO> i po izboru, kada je porozni sloj poluvodiča u kontaktu s kompaktnim slojem poluvodiča n-tipa, a poželjno je da kompaktni sloj poluvodiča n-tipa sadržava TiO».
A method according to claim 1 wherein the maintain-media-busy-signal is transmitted before some or all of the higher data rate data and is used by the transmitting and receiving devices as a synchronising signal for the reception of the higher data rate data for some or all of the remainder of that slot. 
Postupak prema zahtjevu 1, naznačen time, da se vrši prijenos signala održavanja zauzetosti medija, prije nekih ili svih podataka uz veću podatkovnu brzinu, te se upotrebljava putem prijenosnika 1 prijamnika kao sinhronizacijski signal za zaprimanje podataka uz veću podatkovnu brzinu za neki određeni dio ili za sve podatke koji su preostali na tom otvoru.
is hydrogen, halogen, hydroxyl, carboxyl, C14alkyl or C4-7cycloalkyl, said C1-4alkyl and C4-7cycloalkyl can optionally be substituted by 1, 2 or 3 substituents independently selected from the group consisting of: halogen, hydroxyl, carboxyl and amino; 
R* je vodik, halogen, hidroksil, karboksil, C,ualkil ili Cagcikloalkil, spomenuti Crgalkil 1 Cugcikloalkil mogu izborno biti supstituirani s 1, 2 ili 3 supstituenta nezavisno odabranih iz skupine koja se sastoji od: halogena, hidroksila, karboksila i amino;
The compound of any one of claims 1 to 7, wherein G2 is selected from the group below: wherein each R3 is selected from hydroxyl, amino, halogen, alkoxy, alkylamino, dialkylamino, CF3, CN, NO2, sulfonyl, acyl, aliphatic, aryl, heteroaryl and heterocyclic; m is 0, 1, 2 or 3; and R8 is independently hydrogen, acyl or aliphatic. 
Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time da je G2 izabran iz skupine ispod: [image] [image] pri čemu svaki R3 je izabran od hidroksila, amino, halogena, alkoksi, alkilamino, dialkilamino, CF3, CN, NO2, sulfonila, acila, alifatski, arila, heteroarila i heterocikla; m je 0, 1, 2 ili 3; i je neovisno vodik, acil ili alifatski.
However, if both oligosaccharide resistant maltodextrin and polysaccharide resistant maltodextrin are used, it is also preferable to employ a single resistant maltodextrin fraction exhibiting a monomodal distribution of the DP. 
No koriste li se maltodekstrin rezistentan na oligosaharide 1 maltodekstrin Trezistentan na polisaharide, također se daje prednost korištenju jedne maltodekstrinske frakcije koja posjeduje monomodalnu distribuciju DP-a.
A compound of formula (IV): 
Spoj formule (II):